BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 36706956)

  • 1. Visualization of tumor hypoxia and re-oxygenation after stereotactic body radiation therapy in early peripheral lung cancer: A prospective study.
    Inada M; Nishimura Y; Hanaoka K; Nakamatsu K; Doi H; Uehara T; Komanishi M; Ishii K; Kaida H; Hosono M
    Radiother Oncol; 2023 Mar; 180():109491. PubMed ID: 36706956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective clinical trial of tumor hypoxia imaging with 18F-fluoromisonidazole positron emission tomography and computed tomography (F-MISO PET/CT) before and during radiation therapy.
    Tachibana I; Nishimura Y; Shibata T; Kanamori S; Nakamatsu K; Koike R; Nishikawa T; Ishikawa K; Tamura M; Hosono M
    J Radiat Res; 2013 Nov; 54(6):1078-84. PubMed ID: 23589026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-time Tumor Oxygenation Changes After Single High-dose Radiation Therapy in Orthotopic and Subcutaneous Lung Cancer in Mice: Clinical Implication for Stereotactic Ablative Radiation Therapy Schedule Optimization.
    Song C; Hong BJ; Bok S; Lee CJ; Kim YE; Jeon SR; Wu HG; Lee YS; Cheon GJ; Paeng JC; Carlson DJ; Kim HJ; Ahn GO
    Int J Radiat Oncol Biol Phys; 2016 Jul; 95(3):1022-1031. PubMed ID: 27130790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Single Doses of Radiation May Induce Elevated Levels of Hypoxia in Early-Stage Non-Small Cell Lung Cancer Tumors.
    Kelada OJ; Decker RH; Nath SK; Johung KL; Zheng MQ; Huang Y; Gallezot JD; Liu C; Carson RE; Oelfke U; Carlson DJ
    Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):174-183. PubMed ID: 30102194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timing of fluorodeoxyglucose positron emission tomography maximum standardized uptake value for diagnosis of local recurrence of non-small cell lung cancer after stereotactic body radiation therapy.
    Tan D; Gill S; Loh N
    Cancer Med; 2020 Oct; 9(20):7469-7476. PubMed ID: 32846054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment [18F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non-small cell lung cancer treated with definitive radiation therapy: rethinking the role of positron emission tomography in personalizing treatment based on risk status.
    Nair VJ; MacRae R; Sirisegaram A; Pantarotto JR
    Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):312-8. PubMed ID: 24411602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of pretreatment whole-tumor perfusion computed tomography and 18F-fluorodeoxyglucose positron emission tomography/computed tomography measurements on local control of non-small cell lung cancer treated with stereotactic body radiotherapy.
    Aoki M; Akimoto H; Sato M; Hirose K; Kawaguchi H; Hatayama Y; Seino H; Kakehata S; Tsushima F; Fujita H; Fujita T; Fujioka I; Tanaka M; Miura H; Ono S; Takai Y
    J Radiat Res; 2016 Sep; 57(5):533-540. PubMed ID: 27296251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.
    Lovinfosse P; Janvary ZL; Coucke P; Jodogne S; Bernard C; Hatt M; Visvikis D; Jansen N; Duysinx B; Hustinx R
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1453-60. PubMed ID: 26830299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response assessment of stereotactic body radiation therapy using dynamic contrast-enhanced integrated MR-PET in non-small cell lung cancer patients.
    Huang YS; Chen JL; Hsu FM; Huang JY; Ko WC; Chen YC; Jaw FS; Yen RF; Chang YC
    J Magn Reson Imaging; 2018 Jan; 47(1):191-199. PubMed ID: 28480541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of SBRT fractionation in hypoxia dose painting - Accounting for heterogeneous and dynamic tumor oxygenation.
    Kjellsson Lindblom E; Ureba A; Dasu A; Wersäll P; Even AJG; van Elmpt W; Lambin P; Toma-Dasu I
    Med Phys; 2019 May; 46(5):2512-2521. PubMed ID: 30924937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognositc significance of SUV
    Dong M; Liu J; Sun X; Xing L
    J Med Imaging Radiat Oncol; 2017 Oct; 61(5):652-659. PubMed ID: 28266166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic tumor volume on FDG-PET/CT is a possible prognostic factor for Stage I lung cancer patients treated with stereotactic body radiation therapy: a retrospective clinical study.
    Takahashi N; Yamamoto T; Matsushita H; Sugawara T; Kubozono M; Umezawa R; Ishikawa Y; Kozumi M; Katagiri Y; Tasaka S; Takeda K; Takeda K; Dobashi S; Jingu K
    J Radiat Res; 2016 Nov; 57(6):655-661. PubMed ID: 27422935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment maximum standardized uptake value on 18F-fluorodeoxyglucose positron emission tomography is a predictor of outcome for stage I non-small cell lung cancer after stereotactic body radiotherapy.
    Tanaka H; Hayashi S; Hoshi H
    Asia Pac J Clin Oncol; 2016 Mar; 12(1):e113-7. PubMed ID: 24176011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation for local failure by 18F-FDG PET/CT in comparison with CT findings after stereotactic body radiotherapy (SBRT) for localized non-small-cell lung cancer.
    Takeda A; Kunieda E; Fujii H; Yokosuka N; Aoki Y; Oooka Y; Oku Y; Ohashi T; Sanuki N; Mizuno T; Ozawa Y
    Lung Cancer; 2013 Mar; 79(3):248-53. PubMed ID: 23246123
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    De Bruycker S; Vangestel C; Van den Wyngaert T; Pauwels P; Wyffels L; Staelens S; Stroobants S
    J Nucl Med; 2019 Jan; 60(1):34-40. PubMed ID: 29980581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response criteria in solid tumors (PERCIST/RECIST) and SUV
    Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
    Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer.
    Thureau S; Dubray B; Modzelewski R; Bohn P; Hapdey S; Vincent S; Anger E; Gensanne D; Pirault N; Pierrick G; Vera P
    Radiat Oncol; 2018 Oct; 13(1):208. PubMed ID: 30352608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
    Satoh Y; Onishi H; Nambu A; Araki T
    Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic positron emission tomography parameters predict failure patterns in early non-small-cell lung cancer treated with stereotactic body radiation therapy: a single institution experience.
    Lee J; Lee M; Koom WS; Kim HJ; Kim WC
    Jpn J Clin Oncol; 2018 Oct; 48(10):920-926. PubMed ID: 30124920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.
    Okamoto S; Shiga T; Yasuda K; Watanabe S; Hirata K; Nishijima KI; Magota K; Kasai K; Onimaru R; Tuchiya K; Kuge Y; Shirato H; Tamaki N
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2147-2154. PubMed ID: 27251644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.